| 1. |
Blinder KJ, Blumenkranz MS, Bressler NM, et al.Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3[J]. Ophthalmology, 2003, 110(4):667-673.
|
| 2. |
Brown DM, Michels M, Kaiser P, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study[J].Ophthalmology, 2009, 116(1):57-65.DOI: 10.1016/j.Ophtha.2008.10.018.
|
| 3. |
易佐慧子, 陈长征, 郑红梅, 等.抗血管内皮生长因子单克隆抗体ranibizumab治疗病理性近视脉络膜新生血管疗效观察[J].中华眼底病杂志, 2013, 29(4):367-371.DOI:10.3760/cma.j.issn.1005-1015.2013.04.005.Yi ZHZ, Chen CZ, Zheng HM, et al.Clinical observation of intravitreal ranibizumab for treatment of choroidal neovascularization secondary to pathologic myopia[J].Chin J Ocul Fundus Dis, 2008, 24(3):218-219. DOI:10.3760/cma.j.issn.1005-1015.2013.04.005.
|
| 4. |
尹虹, 黎晓新.抗血管内皮生长因子单克隆抗体Bevacizumab玻璃体腔注射治疗高度近视脉络膜新生血管的疗效观察[J].中华眼底病杂志, 2008, 24(3):218-219.Yin H, Li XX.Clinical observation of intravitreal bevacizumab for treatment of choroidal neovascularization secondary to high myopia[J].Chin J Ocul Fundus Dis, 2008, 24(3):218-219.
|
| 5. |
Tufail A, Patel PJ, Sivaprasad S, et al. Ranibuzumab for treatment of choroidal neovascularization secondary to pathological myopia.interim analysis of REPAIR study[J]. Eye (Lond), 2013, 27(6):709-715. DOI: 10.1038/eye.2013.8.
|
| 6. |
Tong JP, Chan WM, Liu DT, et al.Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization[J].Am J Ophthalmol, 2006, 141(3):456-462. DOI:10.1016/j.ajo.2005.10.012.
|
| 7. |
Ciulla TA, Rosenfeld PJ.Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration[J].Curr Opin Ophthalmol, 2009, 20(3): 158-165. DOI: 10.1097/ICU.0b013e32832d25b3.
|
| 8. |
Lai TY, Chan WM, Liu DT, et al.Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia[J]. Retina, 2009, 29:750-756.DOI:10.1097/IAE.0b013e31819ed6bd.
|
| 9. |
Calvo-Gonzalez C, Reche-Frutos J, Donate J, et al.Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and needfor retreatment[J]. Am J Ophthalmol, 2011, 151(3):529-534.DOI: 10.1016/j.ajo.2010.09.021.
|
| 10. |
Monés JM, Amselem L, Serrano A, et al.Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results[J].Eye (Lond), 2009, 23(6):1275-1280.DOI:10.1038/eye.2009.88.
|
| 11. |
Silva RM, Ruiz-Moreno JM, Nascimento J, et al.Short-term efficacy and safety of intravitreal ranibizumab for myopic choroida lneovascularization[J].Retina, 2008, 28(8):1117-1123.DOI:10.1097/IAE.0b013e31817eda41.
|
| 12. |
Konstantinidis L, Mantel I, Pournaras JA, et al.Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization[J].Graefe's Arch Clin Exp Ophthalmol, 2009, 247(3):311-318. DOI: 10.1007/s00417-008-0995-0.
|
| 13. |
Parravano M, Ricci F, Oddone F, et, al. Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization[J].Retina, 2014, 34(10):2053-2062. DOI: 10.1097/IAE.0000000000000201.
|
| 14. |
Lalloum F, Souied EH, Bastuji-Garin S, et al.Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia[J].Retina, 2010, 30(3): 399-406.DOI: 10.1097/IAE.0b013e3181bcef24.
|
| 15. |
Calvo-Gonzalez C, Reche-Frutos J, Donate J, et al.Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment[J]. Am J Ophthalmol, 2011, 151(3):529-534.DOI: 10.1016/j.ajo.2010.09.021.
|
| 16. |
Battaglia Parodi M, Iacono P, Bandello F. Antivascular endothelial growth factor for choroidal neovascularization in pathologic myopia[J]. Dev Ophthalmol, 2010, 46:73-83. DOI: 10.1159/000320010.
|
